Clinical Trial Update: A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study evaluating Azenosertib (ZN-c3) in combination with gemcitabine in patients with osteosarcom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Azenosertib (azenosertib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Conditions: Osteosarcoma | Phase 1 | Status: COMPLETED